新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 辉瑞 » 七大制药巨头与英国MRC签署药物共享协议——探索被忽略化合物的潜在价值

七大制药巨头与英国MRC签署药物共享协议——探索被忽略化合物的潜在价值

来源:生物谷 2014-07-23 10:23

2014年7月23日讯 /生物谷BIOON/ --今日,七大制药巨头已与英国医学研究理事会(MRC)签署协议,同意与英国的学术研究人员分享被忽略的实验性药物,这是行业和外部科学家之间不断深化联系的最新典范。

英国商务大臣文斯·凯布尔(Vince Cable)周二宣布称,英国医学研究理事会(MRC)已与数家制药巨头达成了新的伙伴关系,据此,研究人员将能够获取未被制药公司优先考虑(de-prioritised)的药物化合物。通常情况下,这些药物化合物因未能针对某种特定疾病表现出足够疗效而被搁置或舍弃,但它们仍可能对共享生物学通路的其他疾病有用。

阿斯利康(AZN)、葛兰素史克(GSK)、强生(JNJ)、礼来(Eli Lilly)、辉瑞(Pfizer)、武田(Takeda)、优时比(UCB)均已签署协议加入该计划,该计划建立于阿斯利康与MRC之间一项较早期的公-私项目成功的基础之上。

尽管制药公司通常都不情愿分享其化合物,但目前已逐渐达成共识的是,外部科学家有可能通过采取不同的方法揭开这些药物化合物的价值,从而为企业和学术机构创造共有的利润。(生物谷Bioon.com)

英文原文:Drugmakers to share neglected compounds with British academia

LONDON, July 22 (Reuters) - A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening ties between industry and external scientists.

British business minister Vince Cable announced the new partnership on Tuesday between the Medical Research Council (MRC) and the companies, under which the researchers will gain access to "deprioritised" pharmaceutical compounds.

Often these compounds have been dropped from development because they are not sufficiently effective against a particular condition, but they may still be useful against other diseases with shared biological pathways.

AstraZeneca (NYSE: AZN - news) , GlaxoSmithKline (Other OTC: GLAXF - news) , Johnson & Johnson, Eli Lilly, Pfizer (NYSE: PFE - news) , Takeda and UCB (Brussels: UCB.BR - news) have all signed up to the scheme, which builds on the success of an earlier two-way programme between AstraZeneca and the MRC.

One project under that original 2011 programme involves a drug designed originally to treat acid reflux disease that has now been utilised as a treatment for chronic cough and is being tested in clinical trials.

While drugmakers have traditionally been reluctant to share their compounds, there is a growing recognition that outside experts may be able to unlock value by taking a different approach, resulting in shared profits between companies and academic institutions. (Reporting by Ben Hirschler; Editing by David Goodman)

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库